DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Liver Metastases With Electrochemotherapy

Information source: Institute of Oncology Ljubljana
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Liver Metastases

Intervention: Electrochemotherapy (Procedure)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Institute of Oncology Ljubljana

Official(s) and/or principal investigator(s):
Eldar Gadzijev, MD, PhD, Principal Investigator, Affiliation: Institute of Oncology Ljubljana, Department of Surgical Oncology, Ljubljana, Slovenia
Gregor Sersa, PhD (Biol.), Study Director, Affiliation: Institute of Oncology Ljubljana, Department of Experimental Oncology, Ljubljana, Slovenia

Summary

The aim of the study is to evaluate toxicity and effectiveness of electrochemotherapy with bleomycin in treatment of liver metastases of colorectal cancer in clinical study phase I and II. The study will include 10-15 patients with colorectal cancer with synchronous or metachronous liver metastases, but electrochemotherapy will be performed on metastasis not more than 3 cm in the largest diameter. Treatment effectiveness will be evaluated by magnetic resonance imaging (MRI) and ultrasonography (US) in a monthly interval. Two or three month after the first operation the treated and untreated metastases will be resected and through histological analyses performed. The secondary objectives of the trial are to quantify the impact of the treatment on the patient's quality of life, tolerance to the therapy and suitability for larger study to be conducted.

Clinical Details

Official title: Treatment of Liver Metastases With Electrochemotherapy

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms)

Secondary outcome:

Clinical Evaluation of the Patient (Pain Scale, Adverse Events, Concomitant Treatment)

Treatment Evaluation of Tumor Response - Measurements of Tumor Lesions by Contrast Enhanced Ultrasonography (US-Doppler), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Histology

Detailed description: The study will be conducted on patients with colorectal cancer with synchronous or metachronous liver metastases. Included will be 10-15 patients. Predominantly, patients with synchronous metastases will be included into the study. These patients present liver metastases at the time of primary tumor resection. Electrochemotherapy will be performed on one metastasis not more than 3 cm in largest diameter at the time of the primary tumor operation, but patients have to have at least 2 to 8 metastases. These metastases will be aimed to be resected in the following operation. It is a standard procedure that liver metastases are resected 2-3 months after the primary tumor resection, in the meantime they are on standard chemotherapeutic protocol (FOLFOX, FOLFIRI, Capecitabine). Only in the case of solitary metastasis smaller than 3 cm in diameter, it is resected during the resection of the primary tumor. In the study additional antitumor effectiveness of electrochemotherapy to other treatment (chemotherapy) will be evaluated, compared to non-electrochemotherapy treated metastases. Treatment effectiveness will be evaluated by magnetic resonance imaging (MRI) and ultrasonography (US), in a monthly interval. Two to three month after the first operation the treated and untreated metastases will be resected and thorough histological analysis performed. The second group of patients will be with metachronous liver metastases not larger than 3 cm in diameter, that location is in the vicinity of hollow liver structures and would not be possible to resect them without extensive and potentially jeopardizing liver resection. One of them will be treated by electrochemotherapy. In a month interval treatment effectiveness will be evaluated by MRI. In the case that metastases will decrease in size and to the situation that metastases are resectable, second operation will be performed, metastases resected and thorough histopathological evaluation performed. Otherwise standard treatment procedure will be performed (chemotherapy). All patients will be treated after the procedure is thoroughly described to them, and have signed informed consent.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with measurable liver metastases, presented simultaneously with primary

tumor, aimed at primary tumor resection and in a 2-3 month interval resection of liver metastases. One metastasis will be treated by electrochemotherapy, not larger than 3 cm in diameter.

- Metastasis has to be accessible for application of electrochemotherapy during the

operation, without major liver manipulation or mobilization in order not to create situation that would hamper feasibility of the second operation; resection of metastases.

- Patients with metachronous liver metastases, that are positioned in unresectable

liver area, near blood vessels, but inoperable patients.

- Recurrent liver metastases, not more than 3, that are not larger than 3 cm in

diameter.

- Histologically and cytologically confirmed cancer, any histological differentiation.

- Life expectancy more than 3 month.

- Performance status Karnofsky ≥ 70 or (World Health Organization) WHO ≥ 2.

- Age more than 18.

- The patient must be offered standard treatment.

- Electrochemotherapy is offered to the patients in the case of the disease progression

during the standard treatment, in the case or metastases recurrence, or when they refuse standard treatment.

- Treatment free interval 2-5 weeks, depending on the drugs used.

- Patient must be mentally capable of understanding the information given.

- Patient must give informed consent.

Exclusion Criteria:

- Metastases more than 3 cm in diameter.

- Synchronous unresectable metastases.

- Metachronous unresectable metastases or bigger than 3 cm in diameter.

- Visceral, bone or diffuse metastases.

- Coagulation disturbances.

- Allergic reaction to bleomycin, or cumulative dose of 250 mg/m2 bleomycin received.

- Impaired kidney function (creatinin > 150 µmol/l).

- Patients with hearth failure or pace maker.

- Patients with epilepsy.

- Secondary primary tumor, except surgically treated noninvasive cancer of cervix, or

surgically or irradiated basal cell carcinoma.

- Pregnancy.

Locations and Contacts

Institute of Oncology Ljubljana, Ljubljana 1000, Slovenia
Additional Information

Starting date: November 2008
Last updated: December 19, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017